{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:03:55Z","timestamp":1768370635517,"version":"3.49.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601139"],"award-info":[{"award-number":["81601139"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ5576"],"award-info":[{"award-number":["2024JJ5576"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunogenetics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00251-024-01360-w","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T05:16:38Z","timestamp":1732598198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization"],"prefix":"10.1007","volume":"77","author":[{"given":"Jiaxin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenyang","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-151X","authenticated-orcid":false,"given":"Luo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"2","key":"1360_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","volume":"26","author":"A Bal","year":"2007","unstructured":"Bal A et al (2007) Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol 26(2):211\u2013215","journal-title":"Clin Rheumatol"},{"issue":"4","key":"1360_CR2","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/exd.12934","volume":"25","author":"P Birner","year":"2016","unstructured":"Birner P et al (2016) Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. Exp Dermatol 25(4):305\u2013310","journal-title":"Exp Dermatol"},{"key":"1360_CR3","doi-asserted-by":"crossref","unstructured":"Birney E (2022) Mendelian randomization. Cold Spring Harb Perspect Med 12(4)","DOI":"10.1101\/cshperspect.a041302"},{"issue":"5","key":"1360_CR4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"MJ Brion","year":"2013","unstructured":"Brion MJ, Shakhbazov K, Visscher PM (2013) Calculating statistical power in mendelian randomization studies. Int J Epidemiol 42(5):1497\u20131501","journal-title":"Int J Epidemiol"},{"issue":"2","key":"1360_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1172\/JCI115055","volume":"87","author":"IL Campbell","year":"1991","unstructured":"Campbell IL et al (1991) Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD\/Wehi mice. J Clin Invest 87(2):739\u2013742","journal-title":"J Clin Invest"},{"issue":"6","key":"1360_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/mi.2015.19","volume":"8","author":"JS Choi","year":"2015","unstructured":"Choi JS, Kim KH, Lau LF (2015) The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6. Mucosal Immunol 8(6):1285\u20131296","journal-title":"Mucosal Immunol"},{"issue":"2","key":"1360_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","volume":"38","author":"M Coskun","year":"2017","unstructured":"Coskun M, Vermeire S, Nielsen OH (2017) Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci 38(2):127\u2013142","journal-title":"Trends Pharmacol Sci"},{"issue":"R1","key":"1360_CR8","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","volume":"23","author":"G Davey Smith","year":"2014","unstructured":"Davey Smith G, Hemani G (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23(R1):R89\u201398","journal-title":"Hum Mol Genet"},{"key":"1360_CR9","doi-asserted-by":"publisher","first-page":"k601","DOI":"10.1136\/bmj.k601","volume":"362","author":"NM Davies","year":"2018","unstructured":"Davies NM, Holmes MV, Davey Smith G (2018) Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 362:k601","journal-title":"BMJ"},{"issue":"12","key":"1360_CR10","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1096\/fj.06-5754fje","volume":"20","author":"S Dimitrov","year":"2006","unstructured":"Dimitrov S et al (2006) Sleep enhances IL-6 trans-signaling in humans. Faseb j 20(12):2174\u20132176","journal-title":"Faseb j"},{"issue":"3","key":"1360_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2020-218467","volume":"80","author":"R Felten","year":"2021","unstructured":"Felten R et al (2021) Interleukin 6 receptor inhibition in primary Sj\u00f6gren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis 80(3):329\u2013338","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1360_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cytogfr.2012.04.001","volume":"23","author":"C Garbers","year":"2012","unstructured":"Garbers C et al (2012) Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev 23(3):85\u201397","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"1360_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000096656","volume":"13","author":"J Gay","year":"2006","unstructured":"Gay J et al (2006) Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines. Neuroimmunomodulation 13(2):114\u2013121","journal-title":"Neuroimmunomodulation"},{"issue":"5","key":"1360_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei C et al (2014) Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet 10(5):e1004383","journal-title":"PLoS Genet"},{"key":"1360_CR15","doi-asserted-by":"crossref","unstructured":"Greenbaum CJ, et al (2021) IL-6 receptor blockade does not slow \u03b2 cell loss in new-onset type 1 diabetes. JCI Insight 6(21)","DOI":"10.1172\/jci.insight.150074"},{"issue":"2","key":"1360_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/0016-5085(92)90098-J","volume":"102","author":"V Gross","year":"1992","unstructured":"Gross V et al (1992) Evidence for continuous stimulation of interleukin-6 production in Crohn\u2019s disease. Gastroenterology 102(2):514\u2013519","journal-title":"Gastroenterology"},{"issue":"1","key":"1360_CR17","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1038\/s41467-020-17834-w","volume":"11","author":"C Guo","year":"2020","unstructured":"Guo C et al (2020) Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat Commun 11(1):3924","journal-title":"Nat Commun"},{"issue":"10","key":"1360_CR18","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.2169\/internalmedicine.5215-20","volume":"60","author":"Y Hanioka","year":"2021","unstructured":"Hanioka Y et al (2021) Exacerbation of Ulcerative Colitis with Tocilizumab: a report of two cases, one with Takayasu Arteritis and the other with relapsing polychondritis. Intern Med 60(10):1615\u20131620","journal-title":"Intern Med"},{"issue":"6","key":"1360_CR19","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","volume":"63","author":"M Hibi","year":"1990","unstructured":"Hibi M et al (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63(6):1149\u20131157","journal-title":"Cell"},{"issue":"2","key":"1360_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.166027","volume":"1867","author":"HC Hsu","year":"2021","unstructured":"Hsu HC et al (2021) Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages. Biochim Biophys Acta Mol Basis Dis 1867(2):166027","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1360_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/BF02990576","volume":"40","author":"H Ito","year":"2005","unstructured":"Ito H (2005) Treatment of Crohn\u2019s disease with anti-IL-6 receptor antibody. J Gastroenterol 40:32\u201334","journal-title":"J Gastroenterol"},{"issue":"8","key":"1360_CR22","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1002\/art.23655","volume":"58","author":"C Jandus","year":"2008","unstructured":"Jandus C et al (2008) Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 58(8):2307\u20132317","journal-title":"Arthritis Rheum"},{"key":"1360_CR23","doi-asserted-by":"crossref","unstructured":"Jia D, Zhang F, Li H, Shen Y, Jin Z, Shi FD, Zhang C (2023) Responsiveness to tocilizumab in anti-acetylcholine\u00a0receptor-positive generalized myasthenia gravis. Aging Dis","DOI":"10.14336\/AD.2023.0528"},{"issue":"6","key":"1360_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nmd.2017.03.007","volume":"27","author":"DI Jonsson","year":"2017","unstructured":"Jonsson DI, Pirskanen R, Piehl F (2017) Beneficial effect of tocilizumab in myasthenia gravis refractory to Rituximab. Neuromuscul Disord 27(6):565\u2013568","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"1360_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3892\/mmr.2013.1256","volume":"7","author":"AP Kallaur","year":"2013","unstructured":"Kallaur AP et al (2013) Cytokine profile in relapsing\u2013remitting multiple sclerosis patients and the association between progression and activity of the disease. Mol Med Rep 7(3):1010\u20131020","journal-title":"Mol Med Rep"},{"key":"1360_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155645","volume":"146","author":"Y Kaneko","year":"2021","unstructured":"Kaneko Y, Takeuchi T (2021) An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine 146:155645","journal-title":"Cytokine"},{"issue":"2","key":"1360_CR27","doi-asserted-by":"publisher","first-page":"e002359","DOI":"10.1136\/rmdopen-2022-002359","volume":"8","author":"K Kastrati","year":"2022","unstructured":"Kastrati K et al (2022) A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open 8(2):e002359","journal-title":"RMD Open"},{"key":"1360_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bbrc.2022.06.081","volume":"620","author":"HI Lee","year":"2022","unstructured":"Lee HI et al (2022) IL-6 activates pathologic Th17 cell via STAT 3 phosphorylation in inflammatory joint of Ankylosing Spondylitis. Biochem Biophys Res Commun 620:69\u201375","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1360_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12969-019-0364-z","volume":"17","author":"NL Mallalieu","year":"2019","unstructured":"Mallalieu NL et al (2019) Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. Pediatr Rheumatol Online J 17(1):57","journal-title":"Pediatr Rheumatol Online J"},{"issue":"7","key":"1360_CR30","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1136\/annrheumdis-2016-209275","volume":"75","author":"M Merashli","year":"2016","unstructured":"Merashli M et al (2016) Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis. Ann Rheum Dis 75(7):1418\u20131420","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1360_CR31","first-page":"191","volume":"14","author":"Y Naito","year":"2004","unstructured":"Naito Y et al (2004) Reduced intestinal inflammation induced by dextran sodium sulfate in interleukin-6-deficient mice. Int J Mol Med 14(2):191\u2013196","journal-title":"Int J Mol Med"},{"issue":"6","key":"1360_CR32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/art.11143","volume":"48","author":"H Nakahara","year":"2003","unstructured":"Nakahara H et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48(6):1521\u20131529","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1360_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/intimm\/dxm045","volume":"19","author":"M Nishihara","year":"2007","unstructured":"Nishihara M et al (2007) IL-6-gp130-STAT3 in T cells directs the development of IL-17\u2009+\u2009th with a minimum effect on that of Treg in the steady state. Int Immunol 19(6):695\u2013702","journal-title":"Int Immunol"},{"issue":"8","key":"1360_CR34","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/art.24689","volume":"60","author":"N Okiyama","year":"2009","unstructured":"Okiyama N et al (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60(8):2505\u20132512","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1360_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41467-020-14389-8","volume":"11","author":"N Papadimitriou","year":"2020","unstructured":"Papadimitriou N et al (2020) Physical activity and risks of breast and colorectal cancer: a mendelian randomisation analysis. Nat Commun 11(1):597","journal-title":"Nat Commun"},{"issue":"9","key":"1360_CR36","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1515\/cclm-2023-0086","volume":"61","author":"M Plebani","year":"2023","unstructured":"Plebani M (2023) Why C-reactive protein is one of the most requested tests in clinical laboratories? Clin Chem Lab Med 61(9):1540\u20131545","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"1360_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1399-5448.2007.00243.x","volume":"9","author":"JS Rosa","year":"2008","unstructured":"Rosa JS et al (2008) Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr Diabetes 9(1):9\u201316","journal-title":"Pediatr Diabetes"},{"issue":"Pt 2","key":"1360_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1042\/bj3000281","volume":"300","author":"S Rose-John","year":"1994","unstructured":"Rose-John S, Heinrich PC (1994) Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J 300(Pt 2):281\u2013290","journal-title":"Biochem J"},{"key":"1360_CR39","doi-asserted-by":"publisher","first-page":"919489","DOI":"10.3389\/fimmu.2022.919489","volume":"13","author":"JF Rossi","year":"2022","unstructured":"Rossi JF et al (2022) Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling. Front Immunol 13:919489","journal-title":"Front Immunol"},{"issue":"7","key":"1360_CR40","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1111\/bcp.14725","volume":"87","author":"DK Ryan","year":"2021","unstructured":"Ryan DK et al (2021) Inhibition of interleukin 6 signalling and renal function: a mendelian randomization study. Br J Clin Pharmacol 87(7):3000\u20133013","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1360_CR41","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1038\/s41467-022-29650-5","volume":"13","author":"S Said","year":"2022","unstructured":"Said S et al (2022) Genetic analysis of over half a million people characterises C-reactive protein loci. Nat Commun 13(1):2198","journal-title":"Nat Commun"},{"issue":"2","key":"1360_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4049\/jimmunol.1900755","volume":"205","author":"T Schmit","year":"2020","unstructured":"Schmit T et al (2020) IL-6 Deficiency exacerbates allergic asthma and abrogates the Protective Effect of allergic inflammation against Streptococcus pneumoniae Pathogenesis. J Immunol 205(2):469\u2013479","journal-title":"J Immunol"},{"issue":"4","key":"1360_CR43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/annrheumdis-2012-202470","volume":"72","author":"MM Schoels","year":"2013","unstructured":"Schoels MM et al (2013) Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 72(4):583\u2013589","journal-title":"Ann Rheum Dis"},{"issue":"1\u20132","key":"1360_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jneuroim.2006.03.026","volume":"176","author":"F Scuderi","year":"2006","unstructured":"Scuderi F et al (2006) IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol 176(1\u20132):9\u201315","journal-title":"J Neuroimmunol"},{"issue":"4","key":"1360_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/annrheumdis-2012-202469","volume":"72","author":"JS Smolen","year":"2013","unstructured":"Smolen JS et al (2013) Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 72(4):482\u2013492","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1360_CR46","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1084\/jem.20190344","volume":"216","author":"S Spencer","year":"2019","unstructured":"Spencer S et al (2019) Loss of the interleukin-6 receptor causes immunodeficiency, atopy, and abnormal inflammatory responses. J Exp Med 216(9):1986\u20131998","journal-title":"J Exp Med"},{"issue":"1","key":"1360_CR47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","volume":"17","author":"M Van Roy","year":"2015","unstructured":"Van Roy M et al (2015) The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther 17(1):135","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1360_CR48","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M et al (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet 50(5):693\u2013698","journal-title":"Nat Genet"},{"issue":"8","key":"1360_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-2004-821189","volume":"112","author":"A Wedrychowicz","year":"2004","unstructured":"Wedrychowicz A et al (2004) Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 112(8):435\u2013439","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1360_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108377","volume":"213","author":"H Yang","year":"2020","unstructured":"Yang H et al (2020) Immune-related adverse events of checkpoint inhibitors: insights into immunological dysregulation. Clin Immunol 213:108377","journal-title":"Clin Immunol"}],"container-title":["Immunogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00251-024-01360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00251-024-01360-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00251-024-01360-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:10:31Z","timestamp":1768342231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00251-024-01360-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1360"],"URL":"https:\/\/doi.org\/10.1007\/s00251-024-01360-w","relation":{},"ISSN":["0093-7711","1432-1211"],"issn-type":[{"value":"0093-7711","type":"print"},{"value":"1432-1211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"9 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval can be obtained from the original GWASs. Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\u00a0approval\u00a0Consent for publication"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest\u00a0"}}],"article-number":"3"}}